The effects of butterbur on the histamine and allergen cutaneous response.
BACKGROUND
Butterbur or Petasites hybridus is an herbal remedy that exhibits antihistamine and antileukotriene activity and has been shown to attenuate the response to adenosine monophosphate challenge in patients with allergic rhinitis and asthma. However, no data are available regarding its effects on the histamine and allergen cutaneous response.


OBJECTIVE
To evaluate the effects of butterbur compared with fexofenadine and montelukast on the histamine and allergen wheal and flare cutaneous responses.


METHODS
Atopic patients were randomized into a double-blind, double-dummy, crossover study to receive for 1 week butterbur, 50 mg twice daily (8 AM and 10 PM); fexofenadine, 180 mg once daily (10 PM), and placebo once daily (8 AM); montelukast, 10 mg once daily (10 PM), and placebo once daily (8 AM); or placebo twice daily (8 AM and 10 PM). Patients attended the department at 10 AM and had measurements of the cutaneous wheal and flare responses to histamine, allergen, and saline control at 10-minute intervals for 60 minutes.


RESULTS
Twenty patients completed the study. The mean +/- SE histamine wheal and flare responses, respectively, were significantly attenuated (P < .05) by fexofenadine (9.4 +/- 1.8 mm2 and 13.5 +/- 3.2 mm2) compared with placebo (15.5 +/- 3.3 mm2 and 179.8 +/- 74.3 mm2) but not by butterbur (16.4 +/- 2.1 mm2 and 297.7 +/- 121.2 mm2) or montelukast (19 +/- 1.9 mm2 and 240.2 +/- 66.6 mm2). The allergen wheal and flare responses, respectively, were also significantly attenuated (P < .05) by fexofenadine (31.1 +/- 6.3 mm2 and 256.9 +/- 86.5 mm2) compared with placebo (65.4 +/- 15.2 mm2 and 1,014.5 +/- 250.0 mm2) but not by butterbur (50.4 +/- 9.2 mm2 and 1,110.3 +/- 256.1 mm2) or montelukast (58.8 +/- 9.1 mm2 and 1,463.6 +/- 295.6 mm2).


CONCLUSIONS
Butterbur did not produce any significant effects on the histamine and allergen cutaneous response compared with placebo, whereas mediator antagonism with fexofenadine but not montelukast produced significant attenuation. This finding would suggest that butterbur may not be effective in allergic skin disease.
Jackson
Catherine M
CM
Tayside Centre for General Practice, University of Dundee, Dundee, Scotland.
Lee
Daniel K C
DK
Lipworth
Brian J
BJ
D000085:Acetates / Q000276:immunology / Q000494:pharmacology; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000276:immunology / Q000494:pharmacology; D018592:Cross-Over Studies; D003521:Cyclopropanes; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D006632:Histamine / Q000276:immunology*; D006801:Humans; D008297:Male; D036901:Petasites; D008517:Phytotherapy / Q000379:methods*; D011804:Quinolines / Q000276:immunology / Q000494:pharmacology; D012882:Skin Tests; D013440:Sulfides; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000276:immunology / Q000494:pharmacology
D000085:Acetates; D000893:Anti-Inflammatory Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D016593:Terfenadine; D006632:Histamine; C093230:fexofenadine; C093875:montelukast